مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

372
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

174
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY

Pages

  61-65

Keywords

INTRAVITREAL BEVACIZUMAB (AVASTIN) 

Abstract

 Purpose: To compare the outcomes of treatment with intravitreal bevacizumab (IVB) versus OBSERVATION in CENTRAL SEROUS CHORIORETINOPATHY (CSCR).Methods: In a retrospective comparative study, records of 45 patients with CSCR were reviewed.Twenty‑two patients received IVB (1.25 mg/0.05 ml) while 23 subjects were observed. All subjects underwent measurement of best corrected visual acuity (BCVA) and intraocular pressure (IOP), dilated fundus examination and optical coherence tomography (OCT) imaging at baseline and follow up visits.Outcome measures included central MACULAR THICKNESS (CMT) and BCVA in logarithm of minimum angle of resolution (log MAR) notations.Results: Mean age was 44.1 ± 9.3 (range: 24 to 64) years and mean follow‑p period was 10.4 ± 11.2 (range: 3 to 43, median: 6) months. All patients demonstrated resolution of neurosensory detachment and improvement in visual acuity. At final visit, there was no significant difference in mean CMT between the IVB and OBSERVATION groups (275 vs 284µm, P>0.05). Mean baseline logMAR visual acuity was 0.38 ± 0.24 in the IVB group which improved to 0.24 ± 0.31 at final follow‑p (P=0.011), mean baseline logMAR visual acuity was 0.42 ± 0.28 in the OBSERVATION group and improved to 0.12 ± 0.18 (P=0.001). Visual improvement was more marked in the OBSERVATION group (0.30 vs 0.14 logMAR, P<0.05) and mean final visual acuity was also significantly better (P=0.05).Conclusion: There was no significant difference between IVB injection and OBSERVATION in terms of anatomical outcomes of treatment for CSCR. In terms of visual outcomes, OBSERVATION was superior to IVB injection.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    UNLU, CIHAN, ERDOGAN, GURKAN, AYDOGAN, TUGBA, SEZGIN AKCAY, BETUL ILKAY, KARDES, ESRA, KIRAY, GULUNAY AKCALI, & BOZKURT, TAHIR KANSU. (2016). INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY. JOURNAL OF OPHTHALMIC AND VISION RESEARCH, 11(1), 61-65. SID. https://sid.ir/paper/311611/en

    Vancouver: Copy

    UNLU CIHAN, ERDOGAN GURKAN, AYDOGAN TUGBA, SEZGIN AKCAY BETUL ILKAY, KARDES ESRA, KIRAY GULUNAY AKCALI, BOZKURT TAHIR KANSU. INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY. JOURNAL OF OPHTHALMIC AND VISION RESEARCH[Internet]. 2016;11(1):61-65. Available from: https://sid.ir/paper/311611/en

    IEEE: Copy

    CIHAN UNLU, GURKAN ERDOGAN, TUGBA AYDOGAN, BETUL ILKAY SEZGIN AKCAY, ESRA KARDES, GULUNAY AKCALI KIRAY, and TAHIR KANSU BOZKURT, “INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY,” JOURNAL OF OPHTHALMIC AND VISION RESEARCH, vol. 11, no. 1, pp. 61–65, 2016, [Online]. Available: https://sid.ir/paper/311611/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button